RxDoctor Payments Data

Jagat Rawal, MD

Internal Medicine · Sunnyside, NYNPI 1891775680

Payments from drug & device makers

$3,616in general payments, 2019–2025

Across 82 payments — averaging $44.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • AstraZeneca$564
  • Boston Scientific$249
  • Abbott$150
  • GSK$125
  • Johnson & Johnson$100
  • plus $264 from 6 others

What the payments were for

  • Food & beverage$3,609100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,616 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$258,740
Medicare patients
271
Services billed
2,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$103,316
JanumetSitagliptin Phos/Metformin Hcl71$90,001
OzempicSemaglutide51$74,016
JardianceEmpagliflozin103$58,690
XareltoRivaroxaban85$39,666
KerendiaFinerenone49$36,222
FarxigaDapagliflozin Propanediol51$36,203
EntrestoSacubitril/Valsartan67$34,202
ProliaDenosumab17$27,742
JanuviaSitagliptin Phosphate24$26,125
SantylCollagenase Clostridium Hist.18$25,161
TradjentaLinagliptin50$19,524
Diclofenac Sodium58$19,210
RexultiBrexpiprazole19$18,398
Repatha SureclickEvolocumab17$14,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$103,316210 claims
Johnson & JohnsonXarelto$100$39,66685 claims
BayerKerendia$2,163$36,22249 claims
AstraZenecaFarxiga$564$36,20351 claims
GSKBreo Ellipta$125$4,57212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Sunnyside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →